Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche discontinues depression agent

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche discontinues development of its neurokinin-1 antagonist R-673 for depression due to difficulties distinguishing between placebo and treatment arms in two Phase II trials, the firm says July 20 during its second quarter earnings call. The Phase II data "showed we couldn't get below a 50% response rate with placebo," Pharmaceutical Division CEO William Burns explained. Roche said it is open to outlicensing the agent. Other firms developing neurokinin antagonists include GlaxoSmithKline and Sanofi-Aventis...

You may also be interested in...



Execs On The Move: Promotions Are In The Spotlight At Terumo And MiMedx Group

Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.

COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More

In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

Topics

UsernamePublicRestriction

Register

PS003012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel